Related Experiment Videos
[Determination of TSH receptor antibodies--clinical value]
Abstract:
In 223 patients suffering from Graves' disease, TSH receptor autoantibodies in serum were measured using the commercially available TRAK assay (Henning, Berlin). Of 53 patients examined before treatment, 50 (94%) were TRAK-positive. During drug therapy the number of positive titers decreased. Of 38 patients examined after a therapy course for the first time, only two (5.3%) were positive. Evaluation of antibody status after all three forms of treatment (drugs, surgery, radioiodine) in 146 patients showed that of 33 patients with persistently positive titers only nine relapsed. Of the 24 patients out of this group without relapse, 15 had operative or radioiodine treatment. The 113 patients becoming or remaining TRAK-negative after treatment showed 12 relapses, in all these cases relapse was accompanied or announced by conversion to positive TRAK values. The high sensitivity and specificity of the assay (in a control group of 40 patients with autonomous adenoma no positive TRAK was seen) allow to use the test for discrimination between Graves' disease and disseminated autonomy of the thyroid in patients presenting with diffuse hyperthyroidism. Thus, by helping to establish an exact diagnosis, TRAK could become important for therapy planning. Concerning relapse prediction, our data are less promising since only 39% of patients with persistently positive TRAK titers relapsed. TRAK is not a reliable indicator of relapse risk especially in patients operated or treated with radioiodine. On the other hand, 10% of patients showing negative titers after treatment also relapsed, all turning to positive TRAK values at the same time.
Insights
TSH receptor autoantibodies (TRAK) are highly prevalent in Graves' disease before treatment. While TRAK levels decrease with therapy, they are not a reliable predictor of relapse, though conversion to positive TRAK values often signals recurrence.
Area of Science:
- Endocrinology
- Immunology
Context:
- Graves' disease is an autoimmune disorder characterized by hyperthyroidism.
- Thyroid-stimulating hormone receptor autoantibodies (TRAK) are key diagnostic markers.
- Accurate diagnosis and relapse prediction are crucial for effective management.
Purpose:
- To evaluate the diagnostic utility and prognostic value of TRAK assays in patients with Graves' disease.
- To assess the correlation between TRAK levels and treatment outcomes, including relapse rates.
- To determine the role of TRAK in differentiating Graves' disease from other causes of hyperthyroidism.
Summary:
- A study involving 223 Graves' disease patients measured serum TRAK using the TRAK assay.
- High TRAK positivity (94%) was observed before treatment, decreasing significantly after therapy.
- TRAK assays demonstrated high sensitivity and specificity for diagnosing Graves' disease and differentiating it from thyroid autonomy.
- While TRAK conversion to positive often preceded relapse, persistently positive TRAK titers did not reliably predict recurrence, especially after surgery or radioiodine treatment.
Impact:
- The TRAK assay is valuable for accurate diagnosis of Graves' disease, aiding in therapy planning.
- TRAK monitoring can help identify patients at risk of relapse, although it's not a definitive predictor.
- Understanding TRAK dynamics provides insights into the autoimmune processes of Graves' disease and treatment responses.